Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Entecavir; Tenofovir

Criteria

Inclusion Criteria:

1. Patients received anti-HBV therapy with nucleos(t)ide analogs.

2. Last anti-HBV therapy should continue for at least 2 years.

3. For HBeAg positive patients, HBV DNA should keep negative for at least 1 year after HBeAg seroconversion before the therapy ending; for HBeAg negative patients, HBV DNA should keep negative for at least 2 years before the therapy ending.

Exclusion Criteria:

1. Liver cirrhosis, HCC;

2. Patients with other factors causing active liver diseases;

3. Pregnancy or lactation;

4. Patients with HIV infection or congenital immune deficiency diseases;

5. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.